Results 151 to 160 of about 5,866 (194)
EMA approvals of new medicinal products and new biosimilar products in January and February 2025. [PDF]
Lancet Reg Health EurBurgos JG, Thirstrup S.
europepmc +1 more source
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]
BioDrugsKvien TK +10 more
europepmc +1 more source
Drug Prices, Rebates, and Health Plan Coverage Restrictions. [PDF]
JAMA Netw OpenBeinfeld MT +4 more
europepmc +1 more source
Recruitment of neutrophils by granulocyte colony-stimulating factor in cancer patients undergoing immunotherapy: the good, the bad, and the unknown. [PDF]
Front ImmunolKrykbaeva I, Rupani KV, Liu JM.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2002
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyethylene glycol. It is administered as a single dose per myelosuppressive chemotherapy cycle to decrease the incidence of infection, as manifest by febrile neutropenia, in patients with nonmyeloid cancer.
Monique P, Curran, Karen L, Goa
+6 more sources
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyethylene glycol. It is administered as a single dose per myelosuppressive chemotherapy cycle to decrease the incidence of infection, as manifest by febrile neutropenia, in patients with nonmyeloid cancer.
Monique P, Curran, Karen L, Goa
+6 more sources
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar
BioDrugs, 2019Pegfilgrastim-jmdb/MYL-1401H (FULPHILA™) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylated recombinant granulocyte colony-stimulating factor pegfilgrastim. It is approved for use in patients receiving chemotherapy for malignancy to decrease the incidence of infection, as manifested by febrile neutropenia, in the ...
openaire +2 more sources